Bridgebio Pharma Inc. disclosed positive top-line results from Propel 3, the global phase III pivotal study of oral infigratinib in children with achondroplasia. Change from baseline in annualized ...

Political parties express ongoing concerns over voter roll revisions despite few omissions, awaiting the final list's publication on February 21.

Venture 53 Exits GenLogs as it Targets Next Wave of Freight Tech Disruptors. Exit is Proof of Strategy, Doubles Down ...

It’s déjà vu all over again. Just as the kidney disease space becomes increasingly competitive, Novartis has found itself intending to turn a statistical miss into a regulatory win. | It’s déjà vu all ...

Infigratinib is an investigational oral therapy designed to directly inhibit FGFR3 protein phosphorylation, addressing the underlying cause of achondroplasia.

Ferric citrate significantly improves hemoglobin levels and is well tolerated in patients with NDD CKD and iron deficiency anemia.

ClinicalTrials.gov. NCT04573478. A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function. Available ...

The 2025-26 edition of the Champions League will be back next week when the 16 teams involved in the playoffs will take the ...

BridgeBio Pharma (NASDAQ:BBIO) shares climbed about 9% on Thursday after the biotech group unveiled positive Phase 3 topline ...

Lundbeck will advance the IV formulation of the drug to Phase III trials after the successful Phase IIb trial.

Delve into the details of vertical power delivery and how it surmounts the limits of traditional lateral power when it comes to supporting secondary power rails.

Hair shedding is when hair falls out, while hair loss is when hair stops growing properly.